With our innovative techniques and many years of experience, Creative Biolabs can provide our clients in one-stop CAR development services. Through our advanced CAR construction and evaluation platform, our scientists are confident in TanCAR production with high efficiency and quality.
Chimeric antigen receptors (CARs) are artificial molecules that specificly direct to antigens. CAR, as a therapy for cancer, uses a technique called adoptive cell transfer. T cells are removed from a patient and modified so that they express receptor specificly to the patient’s particular cancer. T cells targeting was mediated through molecules consisting of a target-antigen-specific antibody domain and signaling subunits of the Fc receptor or T cell receptor. Functional implication in CAR research field would likely translate into therapeutic benefits.
However, traditional CAR can’t meet higher requirements. Commonly, downregulation or mutation of target antigens is observed in cancer cells, creating antigen-loss escape variants. With our experienced team and advanced technologies, Creative Biolabs has developed a kind of novel CAR. This novel CAR, in which two distinct antigen recognition domains are present in tandem on a single transgenic receptor, is named TanCAR. This design can enable simultaneous targeting of tumor cells and elements in the tumor microenvironment. Thereby, it can augment T cell activation and function by increasing avidity and broadening their therapeutic reach. Equipped with both facilitating synergistic activation and functionality, TanCARs have much important therapeutic implications.
After the construction of TanCAR, our scientists can offer you a series of services to complete your whole research, including but not limited to CAR cell in vitro assay, CAR preclinical in vivo assay and CAR clinical trials.
Based on our state-of-the-art technology and expertise, Creative Biolabs are remarkable in the construction of tandem Chimeric antigen receptors. Our scientists are pleased to offer customized services to meet your specific demands. If you are interested in our service, please contact us for more details. We will get back to you soon.
Fig.1 Designing a Bispecific TanCAR Molecule.
Zakaria Grada, et al. TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy. Molecular Therapy, 2013, 2, e105.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE